Clinical trials monitoring service
Active Definitive Contract Awarded Last action
- Contract number
- 75N91022C00013
- Awardee
-
Theradex Systems, Inc. UEI HFYTJGWFPMR7
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $44,093,195
Award facts
- Opportunity
-
- Cancer Trials Support Unit Pre-Solicitation · 75N91021R00014 · Posted Sep 10, 2021
- Contract value 29% obligated
-
- $49,717,754.00 Current, with exercised options
- $151,756,070.00 Potential, with all options
- Completion date 45% complete
-
- Current, with exercised options
- Potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- Total Small Business
- Competition
- Full and Open Competition after exclusion of sources · 1 offer Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- Princeton, NJ, USA
- Legislative mandates
-
- Service Contract Act FAR subpart 22.10
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $9,307,613 | |
| Funding Only Action | $6,757,357 | |
| Terminate for Convenience | $0 | |
| Exercise an Option | $2,360,000 | |
| Funding Only Action | $6,445,870 | |
| Exercise an Option | $2,455,000 | |
| Supplemental Agreement for work within scope | $0 | |
| Exercise an Option | $8,524,477 | |
| Funding Only Action | $442,878 | |
| Other Administrative Action | $0 | |
| Original award | $7,800,000 |
Show all 11
About this award
The National Cancer Institute awarded a $151.8M cost-plus-fixed-fee definitive contract to Theradex Systems, Inc. for clinical trials monitoring services. The contract, which began May 1, 2022 and extends through April 30, 2032, is designated as a Total Small Business set-aside and will be performed in Princeton, New Jersey. This award supports NCI's broader indefinite delivery/indefinite quantity multiple award contract vehicle, which seeks to provide comprehensive operational, administrative, regulatory, information technology, and logistical support services to multi-institutional cancer trials led by NCI-supported clinical trial organizations across six designated task areas.
Under the contract, Theradex Systems will deliver support across multiple task areas requiring demonstrated expertise in oncology clinical research, clinical trial operations, and information technology systems. The award is part of a larger IDIQ contract vehicle with an anticipated combined value not to exceed $500M across all contractors over the 10-year ordering period. Task areas three, five, and six under the original solicitation were partially set aside for small business participation, with the base contract for task area two expected to be awarded to a single contractor while multiple contractors may be selected for the remaining task areas. The contract aligns with NAICS codes 541715 and 541712, reflecting scientific research and development services.
Quick answers
Who was awarded contract 75N91022C00013?
75N91022C00013 was awarded to Theradex Systems, Inc. by National Cancer Institute (National Institutes of Health) on May 1, 2022.
How much is contract 75N91022C00013 worth?
The government has obligated $44,093,195 on 75N91022C00013. Its current value, with exercised options, is $49,717,754. Its potential value, with all options, is $151,756,070.
Was contract 75N91022C00013 competed?
The extent of competition for 75N91022C00013 was full and open competition after exclusion of sources. The government received 1 offer. It was set aside: Total Small Business.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award